Quantitative Medicine Program In 2008, C-Path embarked on a visionary journey, setting the stage for innovation in model-informed drug development (MIDD). A piv
Type 1 Diabetes Consortium The T1D Consortium is working to qualify islet autoimmunity antibodies as prognostic biomarkers to be used in the development of t
C-Path and RARE-X Establish New Collaboration for Rare Disease Data Sharing RARE-X and Critical Path Institute align on their mission and commitment for data sharing to improve rare disease research TUCSON,
Rare Disease Innovation and Data Sharing Accelerated by New RDCA-DAP Program C-Path, NORD and FDA host annual meeting, demonstration and launch of new rare disease data and analytics platform. TUCSON, Ariz.
August 7, 2021 Antenatal and perinatal factors influencing neonatal blood pressure: a systematic review
September 14, 2021 Inter-rater reliability of the neonatal adverse event severity scale using real-world Neonatal clinical trial data